# Michael Hofman

Source: https://nuclide.cc/people/hofman-michael/  
Nuclide record `hofman-michael` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.

## Summary

Michael Hofman is Professor of Nuclear Medicine and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence at the Peter MacCallum Cancer Centre in Melbourne. He led proPSMA, which proved that PSMA PET-CT beats conventional imaging for staging high-risk prostate cancer before curative-intent surgery or radiotherapy, and TheraP, the ANZUP trial that showed lutetium-177 PSMA-617 beats cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer. His publications include the proPSMA and TheraP reports, and his trials made Australia a global centre of theranostics. He now leads trials of earlier-line and combination radioligand therapy.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Nuclear Medicine; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence
- Specialisms: Theranostics; PSMA PET; Lutetium-PSMA therapy; Nuclear medicine

## Sources

- Peter MacCallum Cancer Centre: https://www.petermac.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- institutions: [ANZUP Cancer Trials Group](https://nuclide.cc/institutions/anzup/), [Peter MacCallum Cancer Centre](https://nuclide.cc/institutions/peter-mac/)
- trials: [proPSMA](https://nuclide.cc/trials/propsma/), [TheraP (ANZUP 1603)](https://nuclide.cc/trials/therap/)
- ideas: [A university cyclotron network with shared regulatory files for new tracers](https://nuclide.cc/ideas/idea-fund-academic-radiopharma-pipeline/)
- key papers: [LuPSMA trial: single-arm phase 2 study of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-hofman-lupsma-lancet-oncol-2018/), [TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-therap-lancet-2021/)
- roadmaps: [PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha](https://nuclide.cc/roadmaps/psma-theranostics-roadmap/)

---
JSON: https://nuclide.cc/api/v1/entities/hofman-michael.json